Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study

First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action

(2016) Pierre Gueret et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa

(2011) S. T. Olson et al.   BLOOD

Costs of excessive postoperative hemorrhage in cardiac surgery

(2009) Michael C. Christensen et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Cardiac Surgery in Germany during 2008. A Report on Behalf of the German Society for Thoracic and Cardiovascular Surgery

(2009) J. Gummert et al.   THORACIC AND CARDIOVASCULAR SURGEON

The Frequency and Cost of Complications Associated With Coronary Artery Bypass Grafting Surgery: Results from the United States Medicare Program

(2008) Phillip P. Brown et al.   ANNALS OF THORACIC SURGERY

Anticoagulant therapy during cardiopulmonary bypass

(2008) Maryam Yavari et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

The ongoing variability in blood transfusion practices in cardiac surgery

(2008) Stephanie A. Snyder-Ramos et al.   TRANSFUSION